EMA positive opinion for ViiV’s cabotegravir
The drug is an injectable or tablet specifically developed for HIV prevention among certain individuals
Read More
Tag: ViiV
FDA approves ViiV’s novel HIV treatment Rukobia
60% of heavily treatment-experienced patients achieved undetectable viral load after taking the drug
Read More
ViiV selects projects for HIV/COVID-19 response fund
ViiV received more than 400 applications from across the world, with eligible submissions coming from Africa, Asia, Europe, South America and the US
Read More
US approves first dispersible tablet formulation of Tivicay
The formulation and an expanded indication for Tivicay tablets are currently under review in Europe
Read More
ViiV HIV prevention trial stopped early on efficacy
ViiV said cabotegravir was found to be 69% more effective at preventing HIV acquisition than daily oral PrEP with emtricitabine/tenofovir disoproxil (FTC/TDF)
Read More
ViiV unveils £3m fund to study impact of COVID19 on HIV community
It is hoped that the move will help address some of the questions being asked by the HIV community
Read More
ViiV sees first global approval of Cabenuva in Canada
Canada has also approved Vocabria to be used for short time periods in conjunction with the drug.
Read More
ViiV’s HIV regimen hit with setback in the US
US regulators have declined ViiV Healthcare’s application to market an investigational long-acting regimen for the treatment of HIV
Read More
ViiV submits dispersible form of dolutegravir in the US, EU
The company is seeking approval to market the formulation for children with HIV
Read More
ViiV Healthcare submits HIV drug fostemsavir in the US
The treatment could offer a new option for patients unable to reach viral supression
Read More
GSK HIV combo meets main goal in Phase III study
The drug could now be administered every eight weeks compared to every four.
Read More
ViiV secures EU nod for HIV therapy Dovato
Availability of the two-drug regimen is considered a significant development for people with the condition
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
